Impact of Lung Function and Exacerbations on Health-Related Quality of Life in COPD Patients Within One Year: Real-World Analysis Based on Claims Data

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• World Health Organization. The top 10 causes of death; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed September 3, 2021.
   Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442
   PubMed Web of Science ®Google Scholar
• Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316–325. doi:10.1513/AnnalsATS.201309-305OC
   PubMedGoogle Scholar
• Mackay AJ, Kostikas K, Murray L, et al. Patient-reported outcomes for the detection, quantification, and evaluation of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2018;198(6):730–738. doi:10.1164/rccm.201712-2482CI
   PubMed Web of Science ®Google Scholar
• Gemeinsamer Bundesausschuss. Richtlinie Des Gemeinsamen Bundesausschusses Zur Zusammenführung Der Anforderungen an Strukturierte Behandlungsprogramme Nach § 137f Absatz 2 SGB V (DMP-Anforderungen-Richtlinie/DMPA-RL) [Directive of the Federal Joint Committee on the Combination of Requirements for Structured Treatment Programs Pursuant to Section 137f (2) of the German Social Code, Book V (DMP Requirements Directive/DMPA Directive)]; 2021. Available from: https://www.g-ba.de/downloads/62-492-2416/DMP-A-RL_2020-11-20_iK-2021-02-25.pdf. Accessed September 6, 2021.
   Google Scholar
• Wilke S, Jones PW, Müllerova H, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70(5):420–425. doi:10.1136/thoraxjnl-2014-205697
   PubMed Web of Science ®Google Scholar
• Kim S, Oh YM, Jo M. Health-related quality of life in chronic obstructive pulmonary disease patients in Korea. Health Qual Life Outcomes. 2014;12(57):1–7. doi:10.1186/1477-7525-12-57
   Google Scholar
• Wacker ME, Jörres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(1):1–11. doi:10.1186/s12890-016-0238-9
   PubMedGoogle Scholar
• Boland MRS, Tsiachristas A, Kruis AL, Chavannes NH, Rutten-van Mölken MPMH. Are GOLD ABCD groups better associated with health status and costs than GOLD 1234 grades? A Cross-Sectional Study. Prim Care Respir J. 2014;23(1):30–37. doi:10.4104/pcrj.2014.00002
   PubMedGoogle Scholar
• Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–646. doi:10.1183/09031936.00195212
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648. doi:10.1136/bmj.1.6077.1645
   PubMed Web of Science ®Google Scholar
• Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61(6):472–477. doi:10.1136/thx.2005.052449
   PubMed Web of Science ®Google Scholar
• Tantucci C, Modina D. Lung function decline in COPD. Int J COPD. 2012;7:95. doi:10.2147/COPD.S27480
   Google Scholar
• Thomas ET, Guppy M, Straus SE, Bell KJL, Glasziou P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. BMJ Open. 2019;9(6):e028150. doi:10.1136/bmjopen-2018-028150
   PubMed Web of Science ®Google Scholar
• Lutter JI, Jörres RA, Kahnert K, et al. Health-related quality of life associates with change in FEV1 in COPD: results from the COSYCONET cohort. BMC Pulm Med. 2020;20(148):1–12. doi:10.1186/s12890-020-1147-5
   PubMedGoogle Scholar
• de la Loge C, Taugaut B, Fofana F, et al. Relationship between FEV1 and patient-reported outcomes changes: results of a meta-analysis of randomized trials in stable COPD. Chronic Obstr Pulm Dis J COPD Found. 2016;3(2):519. doi:10.15326/jcopdf.3.2.2015.0152
   PubMedGoogle Scholar
• Nagai K, Makita H, Suzuki M, et al. Differential changes in quality of life components over 5 years in chronic obstructive pulmonary disease patients. Int J COPD. 2015;10:745. doi:10.2147/COPD.S77586
   Google Scholar
• Jones PW, Anderson JA, Calverley PMA, et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respir Res. 2011;12(71):1–8. doi:10.1186/1465-9921-12-71
   PubMedGoogle Scholar
• Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes. 2010;8(39):39. doi:10.1186/1477-7525-8-39
   PubMedGoogle Scholar
• Guo J, Chen Y, Zhang W, Tong S, Dong J. Moderate and severe exacerbations have a significant impact on health-related quality of life, utility, and lung function in patients with chronic obstructive pulmonary disease: a meta-analysis. Int J Surg. 2020;78:28–35. doi:10.1016/j.ijsu.2020.04.010
   PubMed Web of Science ®Google Scholar
• Esteban C, Quintana JM, Moraza J, et al. Impact of hospitalisations for exacerbations of COPD on health-related quality of life. Respir Med. 2009;103(8):1201–1208. doi:10.1016/j.rmed.2009.02.002
   PubMed Web of Science ®Google Scholar
• Siebeling L, Musoro JZ, Geskus RB, et al. Prediction of COPD-specific health-related quality of life in primary care COPD patients: a Prospective Cohort Study. NPJ Prim Care Respir Med. 2014;24(14060):1–7. doi:10.1038/npjpcrm.2014.60
   Web of Science ®Google Scholar
• Bellou V, Belbasis L, Konstantinidis AK, Tzoulaki I, Evangelou E. Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal. Br Med J. 2019;367:l5358. doi:10.1136/bmj.l5358
   Web of Science ®Google Scholar
• Esteban C, Arostegui I, Aramburu A, et al. Predictive factors over time of health-related quality of life in COPD patients. Respir Res. 2020;21(138):1. doi:10.1186/s12931-020-01395-z
   PubMedGoogle Scholar
• Bundesministerium für Gesundheit. Mitgliederstatistik KM6; 2017. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM6_2017.xlsx. Accessed September 3, 2021.
   Google Scholar
• Fletcher CM. Standardized questionnaire on respiratory symptoms: a statement prepared for, and approved by, the medical research council’s committee on the aetiology of chronic bronchitis. Br Med J. 1960;2(5213):1665.
   PubMedGoogle Scholar
• Kirsch F, Schramm A, Schwarzkopf L, et al. Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study. Respir Res. 2019;20(1):1–5. doi:10.1186/s12931-019-1179-7
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
   PubMed Web of Science ®Google Scholar
• Mittal R, Chhabra SK. GOLD classification of COPD: discordance in criteria for symptoms and exacerbation risk assessment. COPD J Chronic Obstr Pulm Dis. 2017;14(1):1–6. doi:10.1080/15412555.2016.1230844
   PubMed Web of Science ®Google Scholar
• Smid DE, Franssen FME, Gonik M, et al. Redefining cut-points for high symptom burden of the global initiative for chronic obstructive lung disease classification in 18,577 patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2017;18(12):1097.e11–1097.e24. doi:10.1016/j.jamda.2017.09.003
   Web of Science ®Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736. doi:10.1007/s11136-011-9903-x
   PubMed Web of Science ®Google Scholar
• Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71(6):493–500. doi:10.1136/thoraxjnl-2015-207782
   PubMed Web of Science ®Google Scholar
• Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD assessment test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203. doi:10.1016/S2213-2600(14)70001-3
   PubMed Web of Science ®Google Scholar
• Smid DE, Franssen FME, Houben-Wilke S, et al. Responsiveness and MCID estimates for CAT, CCQ, and HADS in patients with COPD undergoing pulmonary rehabilitation: a prospective analysis. J Am Med Dir Assoc. 2017;18(1):53–58. doi:10.1016/j.jamda.2016.08.002
   PubMed Web of Science ®Google Scholar
• Szentes BL, Schwarzkopf L, Kirsch F, Schramm A, Leidl R. Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L. Expert Rev Pharmacoeconomics Outcomes Res. 2020;20(5):523–529. doi:10.1080/14737167.2019.1662302
   PubMed Web of Science ®Google Scholar
• Zanini A, Aiello M, Adamo D, et al. Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respir Care. 2015;60(1):88–95. doi:10.4187/respcare.03272
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Hastie TJ, Tibshirani RJ. Generalized additive models. Stat Sci. 1986;1(3):297–318. doi:10.1201/9780203753781
   Google Scholar
• Sheskin DJ. Handbook of Parametric and Nonparametric Statistical Procedures. 4th ed. Chapman & Hall/CRC; 2007. doi:10.1201/9780429186196
   Google Scholar
• Donohue JF. Minimal clinically important differences in COPD lung function. COPD J Chronic Obstr Pulm Dis. 2005;2(1):111–124. doi:10.1081/COPD-200053377
   Google Scholar
• Spencer S, Calverley PMA, Burge PS, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163(1):122–128. doi:10.1164/ajrccm.163.1.2005009
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007;101(1):146–153. doi:10.1016/j.rmed.2006.04.001
   PubMed Web of Science ®Google Scholar
• Habraken JM, Van Der Wal G, Riet T, Weersink EJM, Tobene F, Bindels PJE. Health-related quality of life and functional status in end-stage COPD: a Longitudinal Study. Eur Respir J. 2011;37(2):280–288. doi:10.1183/09031936.00149309
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Rodríguez-Blanco T, Llagostera M, et al. Factors associated with changes in quality of life of COPD patients: a Prospective Study in primary care. Respir Med. 2013;107(10):1589–1597. doi:10.1016/j.rmed.2013.05.009
   PubMed Web of Science ®Google Scholar
• Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12(40):1–9. doi:10.1186/1465-9921-12-40
   PubMedGoogle Scholar
• Kiley JP, Ram JS, Croxton TL, Weinmann GG. Challenges associated with estimating minimal clinically important differences in COPD - the NHLBI perspective. COPD J Chronic Obstr Pulm Dis. 2005;2(1):43–46. doi:10.1081/COPD-200050649
   Google Scholar
• Raimondi GA. FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(12):1676–1677. doi:10.1164/rccm.201701-0001LE
   PubMed Web of Science ®Google Scholar
• Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469. doi:10.1183/09031936.00099306
   PubMed Web of Science ®Google Scholar
• Nishimura K, Sato S, Tsukino M, et al. Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2009;7(1):69. doi:10.1186/1477-7525-7-69
   PubMedGoogle Scholar
• Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189(3):250–255. doi:10.1164/rccm.201310-1863PP
   PubMed Web of Science ®Google Scholar
• Cao Z, Ong KC, Eng P, Tan WC, Ng TP. Frequent hospital readmissions for acute exacerbation of COPD and their associated factors. Respirology. 2006;11(2):188–195. doi:10.1111/j.1440-1843.2006.00819.x
   PubMed Web of Science ®Google Scholar
• Zhudenkov K, Palmér R, Jauhiainen A, et al. Longitudinal FEV1 and exacerbation risk in COPD: quantifying the association using joint modelling. Int J COPD. 2021;16:101–111. doi:10.2147/COPD.S284720
   Google Scholar
• Soler-Cataluña JJ, Martínez-García MÁ, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–338. doi:10.1164/rccm.200712-1869OC
   PubMed Web of Science ®Google Scholar
• Mehring M, Donnachie E, Fexer J, Hofmann F, Schneider A. Disease Management Programs for patients with COPD in Germany: a longitudinal evaluation of routinely collected patient records. Respir Care. 2014;59(7):1123–1132. doi:10.4187/respcare.02748
   PubMed Web of Science ®Google Scholar
• Suissa S. Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J. 2008;32(4):829–831. doi:10.1183/09031936.00103008
   PubMed Web of Science ®Google Scholar
• Han MLK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/S2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Allison PJ, Locker D, Feine JS. Quality of life: a dynamic construct. Soc Sci Med. 1997;45(2):221–230. doi:10.1016/S0277-9536(96)00339-5
   PubMed Web of Science ®Google Scholar
• Huber MB, Reitmeir P, Vogelmann M, Leidl R. EQ-5D-5L in the general German population: comparison and evaluation of three yearly cross-section surveys. Int J Environ Res Public Health. 2016;13(3):343. doi:10.3390/ijerph13030343
   PubMed Web of Science ®Google Scholar
• Sood A, Dawson BK, Henkle JQ, Hopkins-Price P, Qualls C. Effect of change of reference standard to NHANES III on interpretation of spirometric “abnormality”. Int J COPD. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695189/ 2007;2(3):361.
   Google Scholar
• Sundh J, Johansson G, Larsson K, et al. Comorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care units. Int J COPD. 2015;10:173. doi:10.2147/COPD.S74645
   Google Scholar
• Bücker B, Löscher S, Schürer C, Schaper K, Abholz -H-H, Wilm S. Asthma in Deutschland: Versorgungslage aus Patientensicht. Eine Fragebogenstudie zum disease-management-programm asthma [Ambulatory care of patients with asthma in Germany and disease management program for asthma from the view of statutory health insured]. DMW Dtsch Medizinische Wochenschrift. 2015;140(6):e60–e66. doi:10.1055/s-0041-101012
   PubMed Web of Science ®Google Scholar